Vanda Pharmaceuticals Inc. (VNDA)

13.57
0.09 0.66
NASDAQ : Health Technology
Prev Close 13.66
Open 13.66
Day Low/High 13.38 / 13.66
52 Wk Low/High 13.00 / 33.44
Volume 287.31K
Avg Volume 718.60K
Exchange NASDAQ
Shares Outstanding 52.96M
Market Cap 711.31M
EPS 0.50
P/E Ratio 32.76
Div & Yield N.A. (N.A)
Interesting VNDA Put And Call Options For February 17th

Interesting VNDA Put And Call Options For February 17th

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new February 17th contracts and identified one put and one call contract of particular interest.

Short Interest In Vanda Pharmaceuticals Falls 10.2%

Short Interest In Vanda Pharmaceuticals Falls 10.2%

The most recent short interest data has been released for the 11/15/2016 settlement date, which shows a 299,736 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 2,633,513, a decrease of 10.22% since 10/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest In Vanda Pharmaceuticals Increases 10.2%

Short Interest In Vanda Pharmaceuticals Increases 10.2%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 272,221 share increase in total short interest for Vanda Pharmaceuticals Inc , to 2,933,249, an increase of 10.23% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals is Now Oversold (VNDA)

Vanda Pharmaceuticals is Now Oversold (VNDA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Vanda Pharmaceuticals At $12, Earn 12.7% Annualized Using Options

Commit To Buy Vanda Pharmaceuticals At $12, Earn 12.7% Annualized Using Options

Investors considering a purchase of Vanda Pharmaceuticals Inc stock, but tentative about paying the going market price of $15.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $12 strike, which has a bid at the time of this writing of 95 cents.

Notable Thursday Option Activity: VNDA, AIRM, LL

Notable Thursday Option Activity: VNDA, AIRM, LL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Vanda Pharmaceuticals Inc , where a total volume of 13,322 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 127.7% of VNDA's average daily trading volume over the past month, of 1.0 million shares.

Vanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling

Vanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling

JMP Securities increased Vanda Pharma's (VNDA) stock price target to $22 from $18 after a judge ruled that a generic drug maker's medication violated the company's patents.

Vanda Pharmaceuticals Stock Sees Short Interest Fall 13%

Vanda Pharmaceuticals Stock Sees Short Interest Fall 13%

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 396,865 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 2,647,162, a decrease of 13.04% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling

A Delaware court ruled Thursday that Roxane Laboratories ANDA product infringes against several Vanda Pharmaceuticals (VNDA) patents for schizophrenia drug Fanapt.

Notable Friday Option Activity: VNDA, BKE, LLNW

Notable Friday Option Activity: VNDA, BKE, LLNW

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vanda Pharmaceuticals Inc , where a total of 4,311 contracts have traded so far, representing approximately 431,100 underlying shares. That amounts to about 90.2% of VNDA's average daily trading volume over the past month of 477,680 shares.

Interesting VNDA Call Options For March 2017

Interesting VNDA Call Options For March 2017

Investors in Vanda Pharmaceuticals Inc saw new options become available today, for the March 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Vanda Pharmaceuticals Stock Sees Short Interest Drop 13%

Vanda Pharmaceuticals Stock Sees Short Interest Drop 13%

The most recent short interest data has been released for the 05/13/2016 settlement date, which shows a 654,026 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 4,420,764, a decrease of 12.89% since 04/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals Stock Sees Short Interest Drop 11.4%

Vanda Pharmaceuticals Stock Sees Short Interest Drop 11.4%

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 650,935 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 5,074,790, a decrease of 11.37% since 04/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 16% Annualized Using Options

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 16% Annualized Using Options

Investors considering a purchase of Vanda Pharmaceuticals Inc stock, but cautious about paying the going market price of $8.63/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 70 cents.

Strong On High Relative Volume: Vanda Pharmaceuticals (VNDA)

Strong On High Relative Volume: Vanda Pharmaceuticals (VNDA)

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate

Short Interest Moves 14.3% Lower For VNDA

Short Interest Moves 14.3% Lower For VNDA

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 1,020,996 share decrease in total short interest for Vanda Pharmaceuticals Inc , to 6,127,734, a decrease of 14.28% since 03/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate

Interesting VNDA Put And Call Options For September 16th

Interesting VNDA Put And Call Options For September 16th

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

3 Biotech Stocks Under $10 Making Big Moves

3 Biotech Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Insiders Love for 2016

5 Stocks Insiders Love for 2016

Insiders at these companies have been scooping up shares of their own stock lately.

Vanda Pharmaceuticals Enters Oversold Territory (VNDA)

Vanda Pharmaceuticals Enters Oversold Territory (VNDA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BOCH, HHC, HMIN, PLCM, PRIM, QLYS, RUBI, SFST, SPTN Downgrades: CCO, CDI, DCO, DIOD, FSTR, IBM, ICON, LIOX, OMCL, QUAD, SAVE, STWD, TIME, VET, VNDA Initiations: HUBS, OMAM, OPHT, OSGB, VBTX Read on to get TheStreet Quant Ratings' detailed report:

First Week of June 2016 Options Trading For Vanda Pharmaceuticals (VNDA)

First Week of June 2016 Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the June 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Vanda Pharmaceuticals (VNDA): Today's Weak On High Volume Stock

Vanda Pharmaceuticals (VNDA): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a weak on high relative volume candidate

Trade-Ideas: Vanda Pharmaceuticals (VNDA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Vanda Pharmaceuticals (VNDA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate

Vanda Pharmaceuticals (VNDA) Weak On High Volume

Vanda Pharmaceuticals (VNDA) Weak On High Volume

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a weak on high relative volume candidate

Intra-Cellular Surges on Optimistic Outlook for Schizophrenia Drug

Intra-Cellular Surges on Optimistic Outlook for Schizophrenia Drug

Schizophrenia patients treated with an experimental drug from Intra-Cellular Therapies reported fewer antipsychotic symptoms compared to a placebo in a large, phase III study, the company said Wednesday.

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a strong on high relative volume candidate

First Week Of VNDA October 16th Options Trading

First Week Of VNDA October 16th Options Trading

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the October 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new October 16th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: C (Hold)